Prevalence of lysosomal storage disorders in Australia from 2009 to 2020

[1]  E. Lisi,et al.  Opinions of adults affected with later‐onset lysosomal storage diseases regarding newborn screening: A qualitative study , 2021, Journal of genetic counseling.

[2]  M. Fuller.  Laboratory Diagnosis of Lysosomal Diseases: Newborn Screening to Treatment. , 2020, The Clinical biochemist. Reviews.

[3]  J. Washburn,et al.  Lessons Learned from Pompe Disease Newborn Screening and Follow-up. , 2020, International journal of neonatal screening.

[4]  J. Washburn,et al.  Lessons Learned from Pompe Disease Newborn Screening and Follow-up , 2020, International journal of neonatal screening.

[5]  Ayesha Ahmad,et al.  Incorporation of Second-Tier Biomarker Testing Improves the Specificity of Newborn Screening for Mucopolysaccharidosis Type I. , 2020, International journal of neonatal screening.

[6]  Ayesha Ahmad,et al.  Incorporation of Second-Tier Biomarker Testing Improves the Specificity of Newborn Screening for Mucopolysaccharidosis Type I , 2020, International journal of neonatal screening.

[7]  B. Davidson,et al.  Lysosomal storage diseases , 2018, Nature Reviews Disease Primers.

[8]  Sean M. Bailey,et al.  The New York Pilot Newborn Screening Program for Lysosomal Storage Diseases: Report of the First 65,000 Infants , 2018, Genetics in Medicine.

[9]  J. Charrow,et al.  Newborn Screening for Lysosomal Storage Disorders in Illinois: The Initial 15‐Month Experience , 2017, The Journal of pediatrics.

[10]  P. Kaplan,et al.  Mucopolysaccharidosis Type I Newborn Screening: Best Practices for Diagnosis and Management. , 2017, The Journal of pediatrics.

[11]  Xuefan Gu,et al.  Demographic characteristics and distribution of lysosomal storage disorder subtypes in Eastern China , 2016, Journal of Human Genetics.

[12]  J. Månsson,et al.  Epidemiology of lysosomal storage diseases in Sweden , 2014, Acta paediatrica.

[13]  R. Howell,et al.  Newborn screening policy development: The Secretary's Advisory Committee on heritable disorders in newborns and children , 2011 .

[14]  M. Elleder,et al.  The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations , 2010, Journal of Inherited Metabolic Disease.

[15]  Y. Chien,et al.  Pompe Disease in Infants: Improving the Prognosis by Newborn Screening and Early Treatment , 2009, Pediatrics.

[16]  J. Savulescu,et al.  An international survey of predictive genetic testing in children for adult onset conditions , 2005, Genetics in Medicine.

[17]  O. Amaral,et al.  Prevalence of lysosomal storage diseases in Portugal , 2004, European Journal of Human Genetics.

[18]  R. A. Wevers,et al.  The frequency of lysosomal storage diseases in The Netherlands , 1999, Human Genetics.

[19]  P. Meikle,et al.  Prevalence of lysosomal storage disorders. , 1999, JAMA.

[20]  E. Beutler,et al.  High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews. , 1991, American journal of human genetics.

[21]  B. Ali,et al.  Prevalence and Novel Mutations of Lysosomal Storage Disorders in United Arab Emirates : LSD in UAE. , 2013, JIMD reports.